- Home
- VBIX vs IPSC Comparison
VBIX vs IPSC Comparison
Compare VBIX & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBIX
- IPSC
- Stock Information
- Founded
- VBIX N/A
- IPSC 2019
- Country
- VBIX Israel
- IPSC United States
- Employees
- VBIX N/A
- IPSC N/A
- Industry
- VBIX Computer Software: Prepackaged Software
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- VBIX Technology
- IPSC Health Care
- Exchange
- VBIX Nasdaq
- IPSC Nasdaq
- Market Cap
- VBIX 44.0M
- IPSC 48.2M
- IPO Year
- VBIX N/A
- IPSC 2021
- Fundamental
- Price
- VBIX $4.49
- IPSC $0.58
- Analyst Decision
- VBIX
- IPSC Strong Buy
- Analyst Count
- VBIX 0
- IPSC 5
- Target Price
- VBIX N/A
- IPSC $3.33
- AVG Volume (30 Days)
- VBIX 43.4K
- IPSC 976.4K
- Earning Date
- VBIX 08-14-2025
- IPSC 08-07-2025
- Dividend Yield
- VBIX N/A
- IPSC N/A
- EPS Growth
- VBIX N/A
- IPSC N/A
- EPS
- VBIX N/A
- IPSC N/A
- Revenue
- VBIX $19,672,000.00
- IPSC $114,898,000.00
- Revenue This Year
- VBIX N/A
- IPSC $1,064.82
- Revenue Next Year
- VBIX N/A
- IPSC N/A
- P/E Ratio
- VBIX N/A
- IPSC N/A
- Revenue Growth
- VBIX N/A
- IPSC 8286.72
- 52 Week Low
- VBIX $0.18
- IPSC $0.34
- 52 Week High
- VBIX $12.00
- IPSC $3.32
- Technical
- Relative Strength Index (RSI)
- VBIX N/A
- IPSC 51.23
- Support Level
- VBIX N/A
- IPSC $0.57
- Resistance Level
- VBIX N/A
- IPSC $0.66
- Average True Range (ATR)
- VBIX 0.00
- IPSC 0.04
- MACD
- VBIX 0.00
- IPSC 0.00
- Stochastic Oscillator
- VBIX 0.00
- IPSC 38.77
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.